American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 Fir...(o income from operations as performan...),Health
Navigation Links
American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter
Date:2/7/2008
o
income from operations as performance measures. Each EBITDA measure is
presented solely as a supplemental disclosure because management believes
that each is a useful performance measure that is widely used within the
industry. In addition, EBITDA measures are significant measurements for
covenant compliance under our credit facility. Each EBITDA measure is not
calculated in the same manner by all companies and, accordingly, may not
be an appropriate measure for comparison.
'/>"/>
| SOURCE American Pacific Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Data From Antheras Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
2. American Red Cross Responds to Tornadoes in the Southeast
3. Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
4. Massive American Red Cross Tornado Relief Effort Spans Five States
5. Sodium Content Foods and Beverages Gain Revenues as Americans are Embracing Low- and No-Sodium Campaigns
6. Vitals.com Goes Red for American Heart Month
7. American Heart Month: Cracking Open Heart Health Myths
8. Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it
9. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
10. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
11. Shareholder Class Action Filed Against American Dental Partners, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
Post Your Comments:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2...is not high levels of cholesterol but low levels t...g that Low levels of Cholesterol maybe linked to d...that men with relatively low cholesterol levels we...oms of severe depression. Edward Suarez, PhD from...
... completion of rough draft sequence of the human ...ieved on 26.06.2000. The project began more than...l letters that make up the recipe of human life. T...the practice of medicine by paving the way for new...
...ional Jewish Medical and Research Center researche...ome may help prevent asthma later in life. Environ...fect in some infants whose homes have high levels ... drive the immune system to produce cytokines that...
...one knows the answer to this one as we do not have...ne cause of kidney failure in the United States, a...s of end-stage renal disease (ESRD)each year. Peop... transplant to stay alive. Almost 25% of patients ...
Other Medicine News:(Date:9/5/2008)...RNewswire-FirstCall/ -- SARcode,Corporation, a pri...itors,to treat inflammatory diseases, and Sunesis ...ed SARcode,s initiation of a Phase 1 clinical tria...T-cell mediated ophthalmic,diseases. Sunesis and S...SARcode with an exclusive license to Sunesis, LFA-...
(Date:9/4/2008)...FirstCall/ -- BioForm Medical,Inc. (Nasdaq: BFRM... of,Polidocanol, conducted in Germany by BioForm M... GmbH (Kreussler), successfully met the study prim... of a New Drug Application,(NDA) process., In the...and safety of,Aethoxysklerol compared to Sodium Te...
(Date:9/4/2008)... More Than 100 Sites in the U.S., ANN ARBOR, Mich... a,privately-held biopharmaceutical company focuse...s to treat endocrine, metabolic and,cardiovascular...a second,Phase 3 clinical trial of Ophena(TM) (osp... therapy in development for the treatment of vagin...
(Date:9/4/2008)...th Two Abstracts Accepted for Presentation, an...RIDGEWATER, N.J., Sept. 4 /- Aegerion... company focused on the treatment of,cardiovascula...ntment of,Peter L. Garrambone, Jr. to the Company,...includes more than 50 pharmaceutical,transactions ...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Stay Ahead of Head Injuries 4766 1Stay Ahead of Head Injuries 4766 2American Red Cross Blood Services Supports Blood Needs of Southern California 4764 1American Red Cross Blood Services Supports Blood Needs of Southern California 4764 2Helix BioPharma Corp announces fiscal 2007 results 1545 1Helix BioPharma Corp announces fiscal 2007 results 1545 2Helix BioPharma Corp announces fiscal 2007 results 1545 3Helix BioPharma Corp announces fiscal 2007 results 1545 4Helix BioPharma Corp announces fiscal 2007 results 1545 5Helix BioPharma Corp announces fiscal 2007 results 1545 6Helix BioPharma Corp announces fiscal 2007 results 1545 7Helix BioPharma Corp announces fiscal 2007 results 1545 8Helix BioPharma Corp announces fiscal 2007 results 1545 9Helix BioPharma Corp announces fiscal 2007 results 1545 10Helix BioPharma Corp announces fiscal 2007 results 1545 11Helix BioPharma Corp announces fiscal 2007 results 1545 12New Scandinavian collaboration boosts nanotech development 1544 1[0] SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases[0] 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment[0] QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome[0] Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
...ial Benefit of Unique OROS(R),Formulation, SAN DIE...use,remains an ongoing concern for parents and phy...on Deficit Hyperactivity Disorder,(ADHD). Data pre...he American Psychiatric Association highlighted fi...d fewer reports of abuse and,lower abuse-related e...
...wire/ -- A new study presented,today showed that r...e, mobility or memory performance in older adults ...o demonstrated, as in,previous studies, that patie...mances on these measures, as compared to placebo.,...ed trial were,presented in a poster at the America...
Other Medicine Technology:New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 3New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 4New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 5New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 2New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 3New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 4Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm.
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish.
Castroviejo tying forceps, straight.
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures.
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |